Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:5280360
Structure:
Synonyms:
(15S)-Prostaglandin E2
(5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic
(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
(Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
363-24-6
5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-
5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI)
5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-,
5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l-
7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
AIDS-003352
AIDS-166064
AIDS003352
AIDS166064
BMS-279654 & PGE2
BSPBio_001490
C00584
C20H32O5
Cervidil
Cervidil (TN)
CHEBI:15551
D00079
Dinoproston
Dinoprostona
Dinoprostona [INN-Spanish]
Dinoprostone
Dinoprostone (JAN/USP/INN)
Dinoprostone [USAN:BAN:INN:JAN]
Dinoprostone [USAN:INN:BAN:JAN]
Dinoprostonum
Dinoprostonum [INN-Latin]
EINECS 206-656-6
Glandin
IDI1_033960
l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
l-PGE2
l-Prostaglandin E2
LMFA03010003
LS-125823
Minprositin E2
Minprostin E2
NCGC00092361-01
NCGC00092361-02
NCGC00092361-03
NCGC00092361-04
NCGC00092361-05
nchembio.106-comp6
nchembio.147-comp12
NSC 165560
NSC 196514
P0409_SIGMA
P5640_SIGMA
P6532_SIGMA
PGE2
PGE2 alpha
PGE2alpha
Prepidil
Prepidil (TN)
Prepidil Gel
Prestwick_793
Propess
Prosta-5,13-dien-1-oic acid, (5Z,11-alpha,13E,15S)-11,15-dihydroxy-9-oxo-
Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-
Prostaglandin E2
Prostaglandin E2 alpha
Prostaglandin E2alpha
Prostin
Prostin E2
Prostin E2 (TN)
SMP2_000056
U 12062
U-12062
ATC-Codes:
Side-Effects:
Side-EffectFrequency
abdominal pain0.0010
vomiting0.0010
fever0.0010
nausea0.0010
diarrhea0.0010
breast tenderness0
vaginitis0
tremor0
tachycardia0
syncope0
pharyngitis0
paresthesia0
weakness0
pain0
nocturnal leg cramps0
hearing loss0
increased sweating0
sepsis0
myalgia0
eye pain0
neck rigidity0
blurred vision0
chills0
urinary retention0
bradycardia0
vulvitis0
wheezing0
myocardial infarction0
dizziness0
dehydration0
cough0
chest pain0
bronchospasm0
back pain0
arthritis0
arthralgia0
arrhythmia0
dyspnea0
endometritis0
rash0
muscle cramps0
laryngitis0
hypotension0
hypertension0
hot flashes0
hiccup0
hemorrhage0
headache0
flushing0
acidosis0

Target

show target details
Uniprot ID:CP1A2_HUMAN
Synonyms:
CYPIA2
Cytochrome P450 1A2
P(3)450
P450 4
P450-P3
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2HI4
Structure:
2HI4

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

15224350
Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells.. H J J Moonen; Y E M Dommels; M van Zwam; M H M van Herwijnen; J C S Kleinjans; G M Alink; T M C M de Kok (2004) Molecular carcinogenesis display abstract
Dietary heterocyclic aromatic amines (HCA) and polyunsaturated fatty acids (PUFA) are both believed to play a role in colon carcinogenesis, and are both substrate for the enzyme cyclooxygenase (COX). In HCA-7 cells, highly expressing isoform COX-2, we investigated the effects of PUFA on prostaglandin synthesis and DNA adduct formation by the HCA 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Furthermore, we studied the role of COX, COX-2 in particular, and cytochrome P4501A2 (CYP1A2) by using the enzyme inhibitors indomethacin (IM), NS-398, and phenethyl isothiocyanate (PEITC), respectively. COX-mediated formation of prostaglandin E2 (PGE2) from linoleic acid (LA) showed that HCA-7 cells can convert LA into arachidonic acid (AA). Alternatively, eicosapentaenoic acid (EPA) was found to compete with AA for COX. Strongly decreased PGE2 levels by addition of IM demonstrated involvement of COX in PUFA metabolism. Both IM and NS-398 inhibited adduct formation by HCA to nearly the same extent, indicating involvement of COX-2 rather than COX-1, while CYP1A2 activity in HCA-7 cells was demonstrated by addition of PEITC. Overall, inhibiting effects were stronger for PhIP than for IQ. HCA-DNA adduct formation was stimulated by addition of PUFA, although high PUFA concentrations partly reduced this stimulating effect. Finally, similar effects for n-3 and n-6 fatty acids suggested that adduct formation may not be the crucial mechanism behind the differential effects of PUFA on colon carcinogenesis that have been described. These results show that COX, and COX-2 in particular, can play a substantial role in HCA activation, especially in extrahepatic tissues like the colon. Furthermore, the obvious interactions between PUFA and HCA in COX-2 expressing cancer cells may be important in modulating colorectal cancer risk.